p53 codon 72 polymorphism and HPV status in lung cancer

Medical Science Monitor

Volumn 14, Issue 9, 2008, Pages

  Buyru, Nur ^a   Altinisik, Julide ^a   Isin, Mustafa ^b   Dalay, Nejat ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

HPV; Lung cancer; p53 codon 72

Indexed keywords

ARGININE; PROLINE; PROTEIN E6; PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CODON; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 52249106249     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin, 2005; 55: 74-108
2. Wood ME, Kelly K, Müllineaux LG, Bunn PA: The Inherited Nature of Lung Cancer: A Pilot Study. Lung Cancer, 2000; 30: 135-44
3. Alexandrie AK, Sundberg MI, Seidegard J et al: Genetic Susceptibility to Lung Cancer with Special Emphasis on CYP1A1 and GSTM1: A Study on Host Factors in Relation to Age at Onset, Gender and Histological Cancer Types. Carcinogenesis, 1994; 15: 1785-90
4. Stancu M, King T, Maizel A: Molecular Biology of Lung Cancer: A Primer. In Weitberg AB, Klastersky J, editors. Cancer of the Lung. Totowa, NJ: Humana Pres, 2002; 81-201
5. Syrjanen KJ: HPV Infections and Lung Cancer. J Clin Pathol, 2002; 55: 885-91
6. Matakidou A, Eisen T, Houlston RS: TP53 Polymorphisms and Lung Cancer Risk: A Systematic Review and Meta-Analysis. Mutagenesis, 2003; 18: 377-85
7. Miller MC, Mohrenweiser HW, Bell DA: Genetic Variability in Susceptibility and Response to Toxicants. Toxicol Lett, 2001; 120: 269-80
8. Vogelstein B, Kiazler KW: p53 Function and Dysfunction. Cell, 1993; 70: 523-26
9. Jensen PA, Page DL: p53: The Promising Story Continuous to Unfold. Hum Pathol, 1993; 24: 455-56
10. Haris CC: p53: At the Crossroads of Molecular Carcinogenesis and Risk Assessment. Science, 1993; 262: 1980-81
11. Pietsch EC, Humbey O, Murphy ME: Polymorphism in the p53 Pathway. Oncogene, 2006; 25: 1602-11
12. Walker KK, Levine AJ: Identification of a Novel p53 Functional Domain that is Necessary for Efficient Growth Suppression. Proc Natl Acad Sci USA, 1996; 93: 15335-40
13. Sakamuro D, Sabbatini P, White E, Prendergast GC: The Polyproline Region of p53 is Required to Activate Apoptosis but not Growth Arrest. Oncogene, 1997; 15: 887-98
14. Buyru N, Tigli H, Dalay N: p53 Codon 72 Polymorphism in Breast Cancer. Oncol Rep, 2003; 10: 711-14
15. Gudleviciene Z, Didziapetriene J, Ramael M et al: Human Papillomavirus and p53 Polymorphism in Lithuanian Cervical Cancer Patients. Gynecol Oncol, 2006; 102(3): 530-33
16. Sayhan N, Yazýcý H, Budak M et al: p53 Codon 72 Genotypes in Colon Cancer. Association with Human Papillomavirus Infection. Res Commun Mol Pathol Pharmacol, 2001; 109: 25-34
17. Perez LO, Abba MC, Dulout FN, Golijow CD: Evaluation of p53 Codon 72 Polymorphism in Adenocarcinomas of the Colon and Rectum. In La Plata, Argentina. Gastroenterol, 2006; 12: 1426-29
18. Fan R, Wu MT, Miller D et al: The p53 Codon 72 Polymorphism and Lung Cancer Risk. Cancer Epidemiology, Biomarkers and Prevention, 2000; 9: 1037-42
19. Papadakis ED, Soulitzis N, Spandidos DA: Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer, 2002; 87(9): 1013-18
20. Jain N, Singh V, Hedan S et al: Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polynorphism in Lung Cancer Patients from India. Chest, 2005; 128: 3999-4007
21. Nadji SA, Mahmoodi M, Ziaee AA et al: An Increased Lung Cancer Risk Associated with Codon 72 Polymorphism in the TP53 Gene and Human Papillomavirus Infection in Mazandaran Province, Iran. Lung Cancer, 2007; 56: 145-51
22. Giuliani L, Jaxmar T, Casadio C et al: Detection of Oncogenic Viruses (SV40, BKV, JVC, HCMV, HPV) and p53 Codon 72 Polymorphism in Lung Carcinoma. Lung Cancer, 2007; 57: 273-81
23. Scheffner M, Werness BA, Huipregtse JM et al: The Eb Oncoprotein Encoded by Human Papillomavirus Type 16 and 18 Promotes the Degradation of p53. Cell, 1990; 63: 1129-36
24. Storey A, Thomas M, Kalita A et al: Role of p53 Polymorphism in the Development of Human Papillomavirus-Associated Cancer. Nature, 1998; 393: 229-34
25. Huibregtse JM, Scheffner M, Howwley PM: A Cellular Protein Mediates Association of p53 with the Eb Oncoprotein of Human Papillomavirus Type 16 or 18. EMBO J, 1991; 10: 4129-35
26. Fei Y, Yang J, Hsieh WC et al: Different Human Papillomavirus 16/18 Infection in Chinese Non-small Cell Lung Cancer Patients Living in Wuhan, China. Jpn J Clin Oncol, 2006; 36(5): 274-79
27. Chiou HL, Wu MF, Liaw YC et al: The Presence of Human Papillomavirus Type 16/18 DNA in Blood Circulation May Act As A Risk Marker of Lung Cancer in Taiwan. Cancer, 2003; 97: 1558-63
28. Talar-Wojnarowska R, Malecka-Panas E: Moelcular Pathogenesis of Pancreatic Adenocarcinoma: Potential Clinical Implications. Med Sci Monit, 2006; 12(9): RA186-93
29. Yang W, Zhang Y, Tian X et al: p53 Codon 72 Polymorphism and the Risk of Esophageal Squamous Cell Carcinoma. Mol Carcinog, 2008; 47: 100-4
30. Kawajiri K, Nakacti K, Imai K et al: Germline Polymorphisms of p53 and CYP1A1 Genes Involved in Human Lung Cancer. Carcinogenesis (Lond), 1993; 14: 1085-89
31. Weston A, Ling-Cawley HM, Caporaso NE et al: Determination of the Allele Frequencies of an L-myc and a p53 Polymorphism in Human Lung Cancer. Carcinogenesis (Lond), 1994; 15: 583-87
32. Murata M, Tagawa M, Kimura M et al: Analysis of a Germline Polymorphism of the p53 Gene in Lung Cancer Patients; Discrete Results with Smoking History. Carcinogenesis (Lond), 1996; 17: 261-64
33. Ferekidis E, Nikolopoulos T, Yiotakis J et al: Correlation of Clinical and Surgical Findings to Histological Features (Koilocytosis, Papillary Hyperplasia) Suggesting Papillomavirus Involvement in the Pathogenesis of Cholesteatoma. Med Sci Monit, 2006, 12(9): CR368-71
34. Park MS, Chang YS, Shin JH et al: The Prevalence of Human Papillomavirus Infection in Korean Non-small Cell Lung Cancer Patients. Yonsei Med J, 2007; 48: 69-77
35. Zafer E, Ergun MA, Alver G et al: Detection and Typing of Human Papillomavirus in Non-small Cell Lung Cancer. Respiration, 2004; 71: 88-90
36. Chen YC, Chen YJ, Richard K et al: Lung Adenocarcinoma and Human Papillomavirus Infection. Cancer, 2004; 101: 1428-36
37. Tsuhako K, Nakazato I, Hirayasu T et al: Human Papillomavirus DNA in Adenosquamous Carcinoma of the Lung. J Clin Pathol, 1998; 51: 741-49
38. Da J, Chen L, Hu Y: Human Papillomavirus Infection and p53 Gene Mutation in Primary Lung Cancer. Zhonghua Zhong Liu Za Zhi, 1996; 18: 27-29
39. Strickler HD, Schiffman TH, Shah KV et al: A Survey of Human Papillomavirus 16 Antibodies in Patients with Epithelial Cancers. Eur J Cancer Prev, 1998; 7: 305-13